Fig. 3From: In patients with severe asthma with eosinophilia in reslizumab clinical trials, high peripheral blood eosinophil levels are associated with low FEV1 reversibilityChange from baseline FEV1 at 52 weeks among patients with high EOS and low reversibility, compared with the overall population excluding these patients. CI confidence interval; EOS blood eosinophil level; FEV1 forced expiratory volume in 1 s; IQR interquartile range; LS least–squaresBack to article page